We pick up the tips for sharing the Sunday newspaper. This week, Midas tips Challenger Bank PCF Group and updates on Joules, The Sunday Times looks at biotech company Immupharma, and The Sunday Telegraph assesses the prospects of Marks & Spencer.
MAIL ON SUNDAY
PCF Group is a rather different challenger bank, says Joanne Hart in this week's Midas column. It has been a bank of just over a year, but it has been a successful company with shares at 37p for almost a quarter of a century.
PCF was founded in 1994 by Scott Maybury and started as an asset finance house and lent money to small businesses so they could buy trucks, vans, tools and the like. Over time, PCF expanded to the consumer market, mainly by helping customers buy used cars.
The loans were financed by bank loans, a model that worked well until the financial crisis, but in 2012 Maybury was determined to reduce banker dependence on PCF and to apply for its own bank license. This was approved last year and deposits have been withdrawn since August 2017.
The bank has already raised £ 140 million in deposits and Maybury believes the company can grow rapidly while retaining its solid record. He has set a credit target of £ 350 million by 2020, and will build up to £ 750 million by 2022.
High driving: PCF Group lends itself to niche customers, such as riders who buy a horse box
The group's financial year ends on September 30 and analysts expect profits of £ 5.2 million to rise to more than £ 8 million in 2019 and £ 10 million the following year.
>>> Read the full Midas column here
THE SUNDAY MEASURES
Immupharma was the darling of the biotech scene and the shares rose by 227 percent in 12 months, making it one of the top 10 biotech artists in the EU, but this position was short-lived, says Sarah Meddings in the column The Sunday Times Inside the City.
The company, which promised to help the five million sufferers suffer, an autoimmune disease that can cause arthritis, kidney problems and hair loss, saw its shares fall 11.7 percent on Friday and ended at an all-time low of 17.9p, compared with a high of 190p.
The problem was that patients on the drug, Lupuzor, showed no significant improvement compared with placebo.
For the results, the company raised £ 10 million from investors, but Meddings says despite the statement by President Tim McCarthy that the drug is still blockbuster potential & # 39; investors have, perhaps, what is the potential that Immupharma has left behind.
THE SUNDAY TELEGRAAF
Marks & Spencer chairman, Archie Norman, says the high street firm will need five years to repair, says James Ashton in the Questor column from The Sunday Telegraph.
With a third consecutive year of declining profits, the city has welcomed the plan that involves closing stores, slowing food expansion, lowering costs and increasing online presence.
Marks & Spencer chairman, Archie Norman, says the firm's headquarters will take five years to solve it
But several investors are not yet buying the recovery plan and the shares have been running water since May.
One of the biggest problems the chain has to deal with is that the web channel and warehousing are wrong, since most digital purchases are collected in stores, and this may be because the home delivery service is rather slow.
The dividend seems safe and if it were cut off, the chairman, and his chief executive Steve Rowe, would face a bitter reaction against Ashton.
There will be no update until November 7 and there is a lot of discussion about where the shares lead. Ashton says he thinks it is not going anywhere fast and must keep his judgment.
What you need to know every week: the This is Money podcast
Do you want to know the most important things you should know about money every week, what attracted our interest and what made us laugh? Listen to the weekly podcast This is Money.
Press play to listen to the full episode of this week below or listen (and subscribe as the podcast) to iTunes, Acast and Audioboom or visit our This is Money Podcast page.